Early lung cancer drug combo trial halted after just 6 patients
NCT ID NCT04638582
First seen May 02, 2026 · Last updated May 14, 2026 · Updated 2 times
Summary
This study aimed to see if giving the immunotherapy drug pembrolizumab, alone or with chemotherapy, before surgery could help people with early-stage non-small cell lung cancer. Only 6 participants were enrolled before the trial was stopped early. The main goal was to measure changes in tumor DNA in the blood and how well the tumor responded to treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER, NONSMALL CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
McGill University Health Center
Montreal, Quebec, H4A3J1, Canada
Conditions
Explore the condition pages connected to this study.